Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 4
48
Diseases
494
Unique genes
0.151
Avg. similarity score
Adrenocortical carcinoma
Most-connected disease (13 links)
Disease
Searched: Anus neoplasms
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
Anus neoplasms
Adrenocortical carcinoma
Choroid plexus carcinoma
Choroid plexus papilloma
Bone osteosarcoma
Sezary syndrome
B-lymphoblastic leukemia/lymphoma
Hemangiosarcoma
Li-fraumeni syndrome
Vulvar lichen sclerosus
Endometrial hyperplasia
Kidney neoplasms
Small cell carcinoma
Urogenital neoplasms
Urologic neoplasms
Demyelinating diseases
Nasopharyngeal carcinoma
Thyroid neoplasms
Transitional cell carcinoma
B-cell chronic lymphocytic leukemia
Breast implant-associated anaplastic large cell lymphoma
Carcinogenesis
Osteosarcoma
Sapho syndrome
B-cell acute lymphoblastic leukemia
CHEK2-related cancer predisposition
Central nervous system neoplasms
Chromosome 17 deletion
Osteogenic sarcoma
Papilloma
Retinoblastoma
Sarcoma
Small cell lung carcinoma
Cervicitis
Cholangiocarcinoma
Familial telangiectasia cancer syndrome
Lymphoblastic leukemia
Merkel cell carcinoma
immune dysregulation, autoimmunity, and autoinflammation
Autoinflammation, immune dysregulation, and eosinophilia
Borderline personality disorder
Gestational trophoblastic disease
Nasopalpebral lipoma-coloboma syndrome
Uinary system neoplasms
granulocytopenia with immunoglobulin abnormality
immunodeficiency 109 with lymphoproliferation
leukemia, acute myeloid, susceptibility to
snijders blok-campeau syndrome
Member diseases (most connected first ‐ the cluster's core)
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| TP53 | 26 / 48 | Adrenocortical carcinoma, B-cell chronic lymphocytic leukemia, B-lymphoblastic leukemia/lymphoma, Bone osteosarcoma and 22 more |
| CDKN2A | 9 / 48 | B-cell acute lymphoblastic leukemia, B-lymphoblastic leukemia/lymphoma, Carcinogenesis, Endometrial hyperplasia and 5 more |
| CCND1 | 8 / 48 | B-cell chronic lymphocytic leukemia, Hemangiosarcoma, Kidney neoplasms, Nasopharyngeal carcinoma and 4 more |
| RB1 | 7 / 48 | Bone osteosarcoma, Osteogenic sarcoma, Osteosarcoma, Retinoblastoma and 3 more |
| KRAS | 6 / 48 | Carcinogenesis, Cholangiocarcinoma, Endometrial hyperplasia, Hemangiosarcoma and 2 more |
| CHEK2 | 5 / 48 | Bone osteosarcoma, CHEK2-related cancer predisposition, Li-fraumeni syndrome, Osteogenic sarcoma and 1 more |
| PTEN | 5 / 48 | Cholangiocarcinoma, Endometrial hyperplasia, Nasopharyngeal carcinoma, Sezary syndrome and 1 more |
| PTGS2 | 5 / 48 | Cholangiocarcinoma, Kidney neoplasms, Papilloma, Thyroid neoplasms and 1 more |
| ARID1A | 4 / 48 | Cholangiocarcinoma, Nasopharyngeal carcinoma, Sezary syndrome, Transitional cell carcinoma |
| BAP1 | 4 / 48 | Central nervous system neoplasms, Cholangiocarcinoma, Kidney neoplasms, Nasopharyngeal carcinoma |
| BRAF | 4 / 48 | Carcinogenesis, Kidney neoplasms, Sezary syndrome, Thyroid neoplasms |
| BRCA2 | 4 / 48 | Breast implant-associated anaplastic large cell lymphoma, Cholangiocarcinoma, Sarcoma, Small cell lung carcinoma |
| EGFR | 4 / 48 | Cholangiocarcinoma, Osteosarcoma, Papilloma, Small cell lung carcinoma |
| ERBB2 | 4 / 48 | Carcinogenesis, Cholangiocarcinoma, Nasopharyngeal carcinoma, Papilloma |
| FLT3 | 4 / 48 | B-cell acute lymphoblastic leukemia, B-lymphoblastic leukemia/lymphoma, leukemia, acute myeloid, susceptibility to, Lymphoblastic leukemia |
| HRAS | 4 / 48 | Hemangiosarcoma, Papilloma, Thyroid neoplasms, Transitional cell carcinoma |
| MYC | 4 / 48 | Demyelinating diseases, Hemangiosarcoma, Merkel cell carcinoma, Osteosarcoma |
| SMARCA4 | 4 / 48 | Sarcoma, Sezary syndrome, Small cell carcinoma, Small cell lung carcinoma |
| TNF | 4 / 48 | Sapho syndrome, Sarcoma, Thyroid neoplasms, Transitional cell carcinoma |
| ATR | 3 / 48 | Familial telangiectasia cancer syndrome, Sarcoma, Urologic neoplasms |
| BCOR | 3 / 48 | Kidney neoplasms, Osteosarcoma, Sarcoma |
| CREBBP | 3 / 48 | Sezary syndrome, Small cell lung carcinoma, Transitional cell carcinoma |
| CSF2 | 3 / 48 | B-cell acute lymphoblastic leukemia, Sarcoma, Thyroid neoplasms |
| CSF3 | 3 / 48 | Hemangiosarcoma, Small cell lung carcinoma, Transitional cell carcinoma |
| CTNNB1 | 3 / 48 | Endometrial hyperplasia, Hemangiosarcoma, Thyroid neoplasms |
| GATA3 | 3 / 48 | B-cell acute lymphoblastic leukemia, B-lymphoblastic leukemia/lymphoma, Carcinogenesis |
| HNF1B | 3 / 48 | Cholangiocarcinoma, Sarcoma, Thyroid neoplasms |
| IKZF1 | 3 / 48 | B-cell acute lymphoblastic leukemia, B-lymphoblastic leukemia/lymphoma, Lymphoblastic leukemia |
| IL32 | 3 / 48 | Cervicitis, Kidney neoplasms, Sezary syndrome |
| IL6 | 3 / 48 | Cholangiocarcinoma, Sarcoma, Thyroid neoplasms |
| KMT2A | 3 / 48 | B-lymphoblastic leukemia/lymphoma, Small cell lung carcinoma, Transitional cell carcinoma |
| KMT2C | 3 / 48 | Cholangiocarcinoma, Sezary syndrome, Transitional cell carcinoma |
| MAPK1 | 3 / 48 | Kidney neoplasms, Sezary syndrome, Thyroid neoplasms |
| PIP4K2A | 3 / 48 | B-cell acute lymphoblastic leukemia, B-lymphoblastic leukemia/lymphoma, Lymphoblastic leukemia |
| PLCG1 | 3 / 48 | Hemangiosarcoma, immune dysregulation, autoimmunity, and autoinflammation, Sezary syndrome |
| SLC5A5 | 3 / 48 | Cholangiocarcinoma, Kidney neoplasms, Thyroid neoplasms |
| SOD2 | 3 / 48 | Kidney neoplasms, Nasopharyngeal carcinoma, Papilloma |
| SOX2 | 3 / 48 | Osteosarcoma, Sarcoma, Small cell lung carcinoma |
| VEGFA | 3 / 48 | Hemangiosarcoma, Osteosarcoma, Urologic neoplasms |
| ABL1 | 2 / 48 | B-lymphoblastic leukemia/lymphoma, Carcinogenesis |
| APC | 2 / 48 | Endometrial hyperplasia, Sarcoma |
| ARID5B | 2 / 48 | B-cell acute lymphoblastic leukemia, Lymphoblastic leukemia |
| ATM | 2 / 48 | B-cell chronic lymphocytic leukemia, Sarcoma |
| BCR | 2 / 48 | B-lymphoblastic leukemia/lymphoma, Lymphoblastic leukemia |
| BRCA1 | 2 / 48 | Breast implant-associated anaplastic large cell lymphoma, Cholangiocarcinoma |
| BRD4 | 2 / 48 | Osteosarcoma, Thyroid neoplasms |
| CCL2 | 2 / 48 | B-cell acute lymphoblastic leukemia, Thyroid neoplasms |
| CDKN1A | 2 / 48 | Papilloma, Transitional cell carcinoma |
| CDKN1B | 2 / 48 | Kidney neoplasms, Sezary syndrome |
| CEBPE | 2 / 48 | B-cell acute lymphoblastic leukemia, Lymphoblastic leukemia |
| CHD3 | 2 / 48 | Sezary syndrome, snijders blok-campeau syndrome |
| EP300 | 2 / 48 | Small cell lung carcinoma, Transitional cell carcinoma |
| GSDMB | 2 / 48 | B-cell acute lymphoblastic leukemia, Lymphoblastic leukemia |
| GSTP1 | 2 / 48 | Osteosarcoma, Sarcoma |
| HYOU1 | 2 / 48 | B-cell acute lymphoblastic leukemia, granulocytopenia with immunoglobulin abnormality |
| IFNA2 | 2 / 48 | Thyroid neoplasms, Transitional cell carcinoma |
| IFNB1 | 2 / 48 | Anus neoplasms, Transitional cell carcinoma |
| IKZF3 | 2 / 48 | B-cell acute lymphoblastic leukemia, B-cell chronic lymphocytic leukemia |
| JAK1 | 2 / 48 | Autoinflammation, immune dysregulation, and eosinophilia, Breast implant-associated anaplastic large cell lymphoma |
| JUN | 2 / 48 | Hemangiosarcoma, Osteosarcoma |
| LHPP | 2 / 48 | B-cell acute lymphoblastic leukemia, Lymphoblastic leukemia |
| MDM2 | 2 / 48 | Li-fraumeni syndrome, Sapho syndrome |
| MET | 2 / 48 | Carcinogenesis, Osteosarcoma |
| MMP2 | 2 / 48 | Nasopharyngeal carcinoma, Osteosarcoma |
| MST1R | 2 / 48 | Nasopharyngeal carcinoma, Osteosarcoma |
| NDRG1 | 2 / 48 | Kidney neoplasms, Small cell lung carcinoma |
| PAX5 | 2 / 48 | B-lymphoblastic leukemia/lymphoma, Lymphoblastic leukemia |
| PIK3CA | 2 / 48 | Nasopharyngeal carcinoma, Sarcoma |
| POU5F1 | 2 / 48 | Carcinogenesis, Gestational trophoblastic disease |
| SIRT1 | 2 / 48 | Demyelinating diseases, Osteosarcoma |
| SLC2A13 | 2 / 48 | Uinary system neoplasms, Urogenital neoplasms |
| SULT1A1 | 2 / 48 | B-cell acute lymphoblastic leukemia, Urologic neoplasms |
| TMEM132D | 2 / 48 | B-cell acute lymphoblastic leukemia, Small cell lung carcinoma |
| TNFRSF9 | 2 / 48 | immunodeficiency 109 with lymphoproliferation, Kidney neoplasms |
| TP63 | 2 / 48 | Lymphoblastic leukemia, Nasopharyngeal carcinoma |
| TPH1 | 2 / 48 | Borderline personality disorder, Kidney neoplasms |
| WDR11 | 2 / 48 | Uinary system neoplasms, Urogenital neoplasms |
| ZDBF2 | 2 / 48 | Nasopalpebral lipoma-coloboma syndrome, Small cell lung carcinoma |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Pathways in cancer | KEGG | 98 / 533 | 4.5× | 3.59e-38 | 1.81e-34 ✓ sig. |
| Prostate cancer | KEGG | 36 / 98 | 8.9× | 2.81e-25 | 4.39e-22 ✓ sig. |
| EGFR tyrosine kinase inhibitor resistance | KEGG | 33 / 80 | 10.0× | 3.45e-25 | 5.32e-22 ✓ sig. |
| Transcriptional misregulation in cancer | KEGG | 47 / 198 | 5.8× | 2.61e-23 | 3.15e-20 ✓ sig. |
| Central carbon metabolism in cancer | KEGG | 27 / 71 | 9.2× | 1.04e-19 | 7.31e-17 ✓ sig. |
| PI3K-Akt signaling pathway | KEGG | 58 / 361 | 3.9× | 1.49e-19 | 1.02e-16 ✓ sig. |
| Human T-cell leukemia virus 1 infection | KEGG | 45 / 224 | 4.9× | 2.99e-19 | 1.95e-16 ✓ sig. |
| Endocrine resistance | KEGG | 30 / 99 | 7.4× | 1.65e-18 | 9.80e-16 ✓ sig. |
| Kaposi sarcoma-associated herpesvirus infection | KEGG | 41 / 196 | 5.1× | 2.66e-18 | 1.55e-15 ✓ sig. |
| Non-small cell lung cancer | KEGG | 26 / 73 | 8.7× | 3.46e-18 | 1.94e-15 ✓ sig. |
| Cellular senescence | KEGG | 36 / 157 | 5.6× | 1.44e-17 | 7.31e-15 ✓ sig. |
| Bladder cancer | KEGG | 20 / 41 | 11.9× | 1.59e-17 | 8.05e-15 ✓ sig. |
| Pancreatic cancer | KEGG | 26 / 77 | 8.2× | 1.61e-17 | 8.07e-15 ✓ sig. |
| Chronic myeloid leukemia | KEGG | 26 / 77 | 8.2× | 1.61e-17 | 8.07e-15 ✓ sig. |
| Human cytomegalovirus infection | KEGG | 43 / 226 | 4.6× | 1.64e-17 | 8.18e-15 ✓ sig. |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| positive regulation of transcription by RNA polymerase II | GO:0045944 | 106 / 1,208 | 3.3× | 7.53e-29 | 3.69e-25 ✓ sig. |
| regulation of cell population proliferation | GO:0042127 | 38 / 201 | 7.2× | 7.81e-22 | 1.63e-18 ✓ sig. |
| positive regulation of cell population proliferation | GO:0008284 | 59 / 532 | 4.2× | 6.21e-21 | 1.13e-17 ✓ sig. |
| cell population proliferation | GO:0008283 | 40 / 263 | 5.8× | 2.47e-19 | 3.56e-16 ✓ sig. |
| positive regulation of gene expression | GO:0010628 | 55 / 504 | 4.1× | 3.08e-19 | 4.34e-16 ✓ sig. |
| negative regulation of cell population proliferation | GO:0008285 | 51 / 444 | 4.3× | 7.38e-19 | 9.60e-16 ✓ sig. |
| apoptotic process | GO:0006915 | 67 / 747 | 3.4× | 1.16e-18 | 1.49e-15 ✓ sig. |
| positive regulation of MAPK cascade | GO:0043410 | 34 / 224 | 5.7× | 1.41e-16 | 1.30e-13 ✓ sig. |
| positive regulation of DNA-templated transcription | GO:0045893 | 65 / 778 | 3.2× | 1.42e-16 | 1.31e-13 ✓ sig. |
| negative regulation of apoptotic process | GO:0043066 | 52 / 524 | 3.8× | 1.83e-16 | 1.65e-13 ✓ sig. |
| regulation of gene expression | GO:0010468 | 45 / 402 | 4.2× | 2.52e-16 | 2.23e-13 ✓ sig. |
| negative regulation of transcription by RNA polymerase II | GO:0000122 | 74 / 1,002 | 2.8× | 7.30e-16 | 5.89e-13 ✓ sig. |
| response to hypoxia | GO:0001666 | 28 / 176 | 6.0× | 2.11e-14 | 1.31e-11 ✓ sig. |
| intrinsic apoptotic signaling pathway in response to DNA damage | GO:0008630 | 17 / 54 | 11.9× | 2.19e-14 | 1.35e-11 ✓ sig. |
| heart development | GO:0007507 | 34 / 273 | 4.7× | 5.82e-14 | 3.37e-11 ✓ sig. |